康方生物：5个新药所有适应证全部谈判成功 纳入国家医保

Core Viewpoint - Kangfang Biopharma successfully negotiated all indications for its five self-developed new drugs to be included in the national medical insurance catalog, marking a significant achievement for the company in expanding access to its innovative therapies [2] Group 1: Drug Development and Approval - All five self-developed new drugs from Kangfang Biopharma have received approval for their respective indications and are now included in the national medical insurance catalog [2] - The newly negotiated dual-antibody drug, Cardunili, and Yivosi have added multiple first-line indications, enhancing their market potential [2] - Three drugs that participated in negotiations for the first time successfully secured inclusion for all their indications in the national medical insurance catalog [2]